Clinical trial to assess the pharmacokinetic/Pharmacodynamic characteristics and safety/tolerability of CKD-519 new formulation in healthy male subjects

Not Applicable

Active, not recruiting

• Conditions: Endocrine, nutritional and metabolic disease

• Registration Number: KCT0001729
• Lead Sponsor: Chong Kun Dang

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 11 March 2019

Recruitment & Eligibility

• Status: Active, not recruiting
• Sex: Male
• Target Recruitment: 30

Inclusion Criteria

1.Between 20 aged and 45 aged in healthy male adult
2.Body weight = 50kg and in the range of calculated BMI(Body Mass Index) 18~29kg/m2
3.Subject who sign on an informed consent form willingly
4.Necessarily he agrees that use double contraceptions and do not sperm donation until two months during clinical trials and after the final dosage of investigational products

Exclusion Criteria

1.Clinically significant disease with cardiovascular, respiratory, hepatobiliary, nephrological, hematological, gastrointestinal, endocrine, immune, integumentary, neurologic, psychiatric system
2.Have a acute disease within 28 days before the beginning of study treatment
3.Have a disease history that can effect drug absorption, distribution, metabolism, excretion
4.Have a clinically significant chronic disease
5.Systolic blood pressure <100mmHg or >140mmHg, diastolic blood pressure<60mmHg or >90mmHg
6.Positive for serology test (HBsAg, anti-HCV Ab, anti-HIV Ab, VDRL(Venereal Disease Research Laboratories))
7.Subject treated ethical drug within 14 days before the beginning of study treatment
8.Subject treated over-the-counter or herbal medicine within 7 days before the beginning of study treatment
9.Have a clinically significant allergic disease (except for mild allergic rhinitis, allergic dermatitis with no drugs)
10.Cannot take standard Meal
11.Whole blood donation within 60 days prior to the first dosing or component blood donation within 20 days prior to the first dosing
12.Blood transfusion within 30 days
13.Taking drugs have received any other investigational drug within 90 days prior to the first dosing
14.Continuously taking caffeine(>5 cups/day), drinking alcohol(>30g/day), smoking excessive cigarettes(>10cigarettes/day)
15.Impossible on who participants in clinical trial by investigator's decision including laboratory test result or another reasone(for example, noncompliance, a disobliging manner)
16.Subject treated metabolizing enzyme inducers or inhibitors including barbiturates within 30 days

Study & Design

• Study Type: Interventional Study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Cmax of CKD-519 ;Tmax of CKD-519;AUClast of CKD-519 ;AUC0-8 of CKD-519 ;t1/2 of CKD-519;CL/F of CKD-519;Vd/F of CKD-519

Secondary Outcome Measures

Name	Time	Method
Tmax of CKD-519 CETP(Cholesteryl ester transfer protein) Activity ;Emax of CKD-519 CETP Activity ;AUEC of CKD-519 CETP Activity ;EC50(half maximal effective concentration ) of CKD-519 CETP Activity